Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
More Than a Gut Feeling─A Combination of Physiologically Driven Dissolution and Pharmacokinetic Modeling as a Tool for Understanding Human Gastric Motility.
Romański M, Staniszewska M, Dobosz J, Myslitska D, Paszkowska J, Kołodziej B, Romanova S, Banach G, Garbacz G, Sarcevica I, Huh Y, Purohit V, McAllister M, Wong SM, Danielak D. Romański M, et al. Among authors: paszkowska j. Mol Pharm. 2024 Aug 5;21(8):3824-3837. doi: 10.1021/acs.molpharmaceut.4c00117. Epub 2024 Jul 3. Mol Pharm. 2024. PMID: 38958668 Free PMC article.
In Vitro Simulation of the Fasted Gastric Conditions and Their Variability to Elucidate Contrasting Properties of the Marketed Dabigatran Etexilate Pellet-Filled Capsules and Loose Pellets.
Staniszewska M, Myslitska D, Romański M, Polak S, Garbacz G, Dobosz J, Smoleński M, Paszkowska J, Danielak D. Staniszewska M, et al. Among authors: paszkowska j. Mol Pharm. 2024 May 6;21(5):2456-2472. doi: 10.1021/acs.molpharmaceut.4c00025. Epub 2024 Apr 3. Mol Pharm. 2024. PMID: 38568423
An extension of biorelevant fed-state dissolution tests to clinical pharmacokinetics - A study on gastrointestinal factors influencing rivaroxaban exposure and efficacy in atrial fibrillation patients.
Romański M, Giebułtowicz J, Gniazdowska E, Piotrowski R, Żuk A, Kułakowski P, Paszkowska J, Myslitska D, Sczodrok J, Garbacz G, Danielak D. Romański M, et al. Among authors: paszkowska j. Int J Pharm. 2024 Jan 5;649:123626. doi: 10.1016/j.ijpharm.2023.123626. Epub 2023 Nov 23. Int J Pharm. 2024. PMID: 38000647
A Rational Approach to Predicting Immediate Release Formulation Behavior in Multiple Gastric Motility Patterns: A Combination of a Biorelevant Apparatus, Design of Experiments, and Machine Learning.
Staniszewska M, Romański M, Polak S, Garbacz G, Dobosz J, Myslitska D, Romanova S, Paszkowska J, Danielak D. Staniszewska M, et al. Among authors: paszkowska j. Pharmaceutics. 2023 Jul 31;15(8):2056. doi: 10.3390/pharmaceutics15082056. Pharmaceutics. 2023. PMID: 37631270 Free PMC article.
Application of a novel PhysioCell apparatus for biopredictive dissolution tests of oral immediate release formulations - A case study workflow for in vitro-in vivo predictions.
Romański M, Staniszewska M, Paszkowska J, Dobosz J, Romanova S, Pieczuro J, Kątny M, Roznerska D, Szczepański J, Schraube M, Renn-Hojan M, Puk E, Hrem O, Garbacz G, Danielak D. Romański M, et al. Among authors: paszkowska j. Int J Pharm. 2023 Jun 25;641:123061. doi: 10.1016/j.ijpharm.2023.123061. Epub 2023 May 19. Int J Pharm. 2023. PMID: 37211237
Conjunction of semi-mechanistic in vitro-in vivo modeling and population pharmacokinetics as a tool for virtual bioequivalence analysis - a case study for a BCS class II drug.
Danielak D, Paszkowska J, Staniszewska M, Garbacz G, Terlecka A, Kubiak B, Romański M. Danielak D, et al. Among authors: paszkowska j. Eur J Pharm Biopharm. 2023 May;186:132-143. doi: 10.1016/j.ejpb.2023.03.014. Epub 2023 Apr 2. Eur J Pharm Biopharm. 2023. PMID: 37015321 Free article.
18 results